Loading patent…
AssigneeShanghai Longyao Biotechnology Inc., Ltd.
InventorsXuanming Yang, Yangxin Fu, Xin Wang, Shengqin Ye, Fanlin Li, Huihui Zhang
Estimating the term…
Provided by the present invention is a chimeric antigen receptor comprising a co-stimulatory receptor, the chimeric antigen receptor having a structure of scFv(X)-(Y)CD3zeta-2A-(Z); X comprises a tumortargeting antibody or a ligand or receptor capable of specifically binding to a tumor; Y is an intracellular region of the co-stimulatory receptor, and Z is a co-stimulatory receptor that is selected from among ICOS, CD28, CD27, HVEM, LIGHT, CD40L, 4-1BB, OX40, DR3, GITR, CD30, TIMI, SLAM, CD2, CD226. Further provided by the present invention are CAR-T cells that are constructed by means of a recombinant expression vector of the described chimeric antigen receptor, a preparation method therefor and an application thereof. The CAR-T cells described in the present invention significantly improve the tumor-killing abilities and amplification abilities thereof.
A fusion protein, which comprises, from N-terminus to C-terminus, (a) a chimeric antigen receptor (CAR) that specifically binds to a CD20, (b) a 2A peptide and (c) a OX40 protein wherein;
A method of treating a B cell lymphoma expressing CD20 in a human subject, comprising administrating to the subject a CAR-T cell comprising an expression vector comprising a nucleotide sequence encoding a fusion protein comprising, from N-terminus to C-terminus, a chimeric antigen receptor (CAR) that specifically binds to human CD20 which comprises SEQ ID NO:
Dependencies are inferred from the claim text.